Published in Hepatitis Weekly, December 28th, 2009
"The outcome is deemed to depend on the liver cell type addressed. Recent gene knock-out studies focused on the role of NF-kappa B in hepatocytes, whereas the role of NF-kappa B in Kupffer cells has not yet been investigated in vivo. Here we present a novel approach, which may be suitable for clinical application, to selectively target NF-kappa B in Kupffer cells and analyse the effects in experimental models...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.